Pfizer (PFE) Long-Term Investments (2009 - 2026)

Pfizer (PFE) has 18 years of Long-Term Investments data on file, last reported at $1.6 billion in Q1 2026.

• Long-Term Investments for Q1 2026 came in at $1.6 billion, down 19.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 billion (down 19.27% YoY), and the FY2025 annual result was $1.6 billion, down 27.24% from the prior year.
• Long-Term Investments was little changed at $1.6 billion in Q1 2026 per PFE's latest filing, from $1.6 billion in the prior quarter.
• Over five years, Long-Term Investments peaked at $16.0 billion in Q2 2022 and troughed at $224.0 million in Q2 2025.
• A 5-year average of $8.0 billion and a median of $9.8 billion in 2022 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2022 and 2025: Long-Term Investments soared 87.23% in 2022, then plunged 97.13% in 2025.
• A 5-year view of Long-Term Investments shows it stood at $10.8 billion in 2022, then jumped by 41.98% to $15.4 billion in 2023, then plunged by 85.5% to $2.2 billion in 2024, then slipped by 27.24% to $1.6 billion in 2025, then advanced by 0.31% to $1.6 billion in 2026.
• Business Quant data shows PFE's Long-Term Investments at $1.6 billion in Q1 2026, $1.6 billion in Q4 2025, and $2.1 billion in Q3 2025.